Skip to main content

Table 1 Clinical characteristics of all patients

From: Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?

Characteristics All EGFR-Mutated ALK-Rearranged
N = 177 % N = 155 % N = 22 %
Age
 Median (range), years 65 (34–89) 65 (34–89) 57.5 (35–77)
Sex
 Male 82 46.3 69 44.5 13 59.1
 Female 95 53.6 86 55.4 9 40.9
Smoking status
 Never-smoker 93 52.5 84 54.2 9 40.9
 Current or former smoker 79 44.5 66 42.5 13 59.1
 Unknown 5 2.8 5 3.2 0 0
 Pack-yearsaMedian (range) 26 (2–114) 27 (2–114) 17 (5–60)
ECOG performance status
 0 96 54.2 83 53.5 13 59.1
 1 54 30.5 46 29.6 8 36.4
 2 11 6.2 11 7.1 0 0
  > 2 10 5.5 9 5.8 1 4.5
 Unknown 6 3.3 6 3.8 0 0
Tumor histology
 Adenocarcinoma 165 93.2 145 93.5 20 90.9
 Adenosquamous carcinoma 4 2.2 4 2.6 0 0
 Squamous 2 1.1 1 0.64 1 4.5
 NSCLC, NOS 2 1.1 1 0.64 1 4.5
 Pleomorphic carcinoma 1 0.56 1 0.64 0 0
 Unknown 3 1.6 3 3.9 0 0
Stage
 Postoperative relapse 72 40.6 64 41.3 8 36.4
 III 8 4.5 4 2.6 4 18.2
 IV 97 54.8 87 56.1 10 45.4
Presence of extrathoracic metastasesb c
 Yes 113 63.8 100 64.5 13 59.1
 No 64 36.1 55 35.4 9 40.9
Presence of brain metastasesb
 Yes 45 25.4 41 26.4 4 18.2
 No 132 74.5 114 73.5 18 81,8
Treatment All EGFR-Mutated ALK-Rearranged
Number of chemotherapeutic regimens, Median 3 (1–14) 3 (1–14) 3 (1–9)
(range) 2(0–7) 2 (0–7) 1 (0–4)
Molecular targeted drugs 1 (0–7) 1 (0–7) 1 (0–5)
Cytotoxic chemotherapy
Immunotherapy
0 (0–2) 0 (0–2) 0 (0–1)
  1. a pack year among Current or former smoker.
  2. b patients with radiologically proven extrathoracic or brain metastases before the start of first chemotherapy.
  3. c patients with pleurat effusion was not included in extrathoracic metastases